Physician profile
Mary Romanic
NPI 1467554097
$5,705.83
in general payments reported to CMS, 2019-2025
30 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,933 · 2020: $401 · 2021: $292 · 2022: $321 · 2023: $873 · 2024: $939 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,658.43 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,172.77 | 2019-2025 | Enbrel, Otezla, Otezla |
| Abbvie INC. | $802.16 | 2019-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $541.35 | 2019-2025 | |
| Ucb, INC. | $365.19 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $344.14 | 2019-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $267.08 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $263.17 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $241.21 | 2019-2024 | Orencia |
| Pfizer INC. | $207.68 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $204.32 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $176.18 | 2020-2025 | Acthar |
| Radius Health, INC. | $132.56 | 2022-2025 | Tymlos |
| Vifor Pharma, INC. | $128.44 | 2019-2022 | |
| Medtronic, INC. | $106.43 | 2023 | Intellis Adaptivestim |
| Celgene Corporation | $94.03 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $89.83 | 2019-2023 | Krystexxa |
| Sobi, INC | $77.77 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $65.03 | 2023-2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $56.93 | 2019-2023 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $51.14 | 2019-2023 | Saphnelo |
| Mallinckrodt Enterprises LLC | $49.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.97 | 2023 | Cyltezo |
| Otsuka America Pharmaceutical, INC. | $38.91 | 2019 | |
| Lilly USA, LLC | $34.72 | 2019 | |
| Sandoz INC. | $29.12 | 2023 | Hyrimoz |
| Genzyme Corporation | $27.63 | 2025 | |
| Antares Pharma, INC. | $20.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.49 | 2024 | |
| Shire North American Group INC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Romanic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.